HiberCell

📍 New York, United States🗓 Founded 2019👥 35 employees💰 Last funded Feb 2019
Biotechnology Research🌐 hibercell.com
Website LinkedIn
HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in HiberCell?
HiberCell has 1 investors on record on gritt.io, including 1 early-stage backers.
When did HiberCell last raise funding?
The most recent investment in HiberCell recorded on gritt.io was in February 2019.
When was HiberCell founded?
HiberCell was founded in 2019.
What industry is HiberCell in?
HiberCell operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is HiberCell based?
HiberCell is headquartered in New York, United States.